MA32027B1 - Preparation de capsules - Google Patents

Preparation de capsules

Info

Publication number
MA32027B1
MA32027B1 MA33030A MA33030A MA32027B1 MA 32027 B1 MA32027 B1 MA 32027B1 MA 33030 A MA33030 A MA 33030A MA 33030 A MA33030 A MA 33030A MA 32027 B1 MA32027 B1 MA 32027B1
Authority
MA
Morocco
Prior art keywords
pharmaceutically active
liquid
solid
capsule
preparation
Prior art date
Application number
MA33030A
Other languages
Arabic (ar)
English (en)
Inventor
Yoshihiro Uchiyama
Tomohiro Yoshinari
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32027B1 publication Critical patent/MA32027B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une préparation de capsules contenant des principes pharmaceutiquement actifs liquide et solide, qui a d'excellentes propriétés de libération des principes pharmaceutiquement actifs. De façon spécifique, l'invention porte sur une capsule contenant des principes pharmaceutiquement actifs, liquide et solide, le principe pharmaceutiquement actif liquide étant scellé à l'intérieur de la capsule sous la forme d'une composition pharmaceutique liquide, et le principe pharmaceutiquement actif solide étant dispersé dans une couche de coque de capsule.
MA33030A 2008-01-10 2010-07-16 Preparation de capsules MA32027B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008003634 2008-01-10
PCT/JP2008/073875 WO2009087938A1 (fr) 2008-01-10 2008-12-29 Préparation de capsules

Publications (1)

Publication Number Publication Date
MA32027B1 true MA32027B1 (fr) 2011-01-03

Family

ID=40853060

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33030A MA32027B1 (fr) 2008-01-10 2010-07-16 Preparation de capsules

Country Status (21)

Country Link
US (1) US20100285121A1 (fr)
EP (3) EP2229939A4 (fr)
JP (1) JP5421126B2 (fr)
KR (1) KR20100111292A (fr)
CN (3) CN101969932A (fr)
AU (1) AU2008345848B2 (fr)
BR (1) BRPI0822019A2 (fr)
CA (1) CA2711814A1 (fr)
CO (1) CO6290641A2 (fr)
CR (1) CR11625A (fr)
DO (3) DOP2010000214A (fr)
EA (3) EA201070835A1 (fr)
EC (1) ECSP10010395A (fr)
IL (1) IL206791A0 (fr)
MA (1) MA32027B1 (fr)
MX (1) MX2010007609A (fr)
MY (1) MY157189A (fr)
NZ (3) NZ587019A (fr)
UA (3) UA102478C2 (fr)
WO (1) WO2009087938A1 (fr)
ZA (1) ZA201004793B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
JP6176894B2 (ja) 2009-03-09 2017-08-09 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
WO2010127103A1 (fr) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Composition pharmaceutique stable et ses procédés d'utilisation
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
CA2781525C (fr) * 2009-10-23 2020-05-12 Pronova Biopharma Norge As Capsules ou comprimes enrobes d'un melange oleagineux d'acides gras
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CA2706272C (fr) * 2010-06-03 2020-05-05 Accucaps Industries Limited Capsules multiphases de gel mou, appareil et procede pour celles-ci
CA2706270C (fr) * 2010-06-03 2020-01-07 Accucaps Industries Limited Formulations pharmaceutiques de statines et d'acides gras omega-3 pour encapsulation
US8609138B2 (en) * 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) * 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
JP5876695B2 (ja) 2011-09-29 2016-03-02 森下仁丹株式会社 シームレスカプセルおよびその製造方法
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
EP2800469B1 (fr) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
EP3348262A1 (fr) 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Procédés pour la préparation des compositions enrichies en dpa d'acides gras oméga-3 polyinsaturés sous forme d'acide libre
JP6173437B2 (ja) * 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
WO2013176455A1 (fr) 2012-05-22 2013-11-28 건일제약 주식회사 Forme à enrobage multicouche de composition pharmaceutique à administration par voie orale contenant un acide gras oméga-3 ou un ester alkylique de celui-ci et un médicament à base de statine
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
CN102824640A (zh) * 2012-08-06 2012-12-19 济南圣泉唐和唐生物科技有限公司 一种胶囊壳及其制备方法
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140249200A1 (en) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6617562B2 (ja) * 2014-01-31 2019-12-11 森下仁丹株式会社 反芻動物用の経口投与剤およびそれを含む反芻動物用飼料
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10278898B2 (en) * 2014-06-26 2019-05-07 R.P. Scherer Technologies, Llc Methods for manufacturing encapsulated granular material, methods for drying coating materials, and fluidized bed dryers
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN104940654A (zh) * 2015-06-24 2015-09-30 黄红林 一种葛根胶囊
KR101950907B1 (ko) 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20210137917A1 (en) * 2018-04-09 2021-05-13 Intas Pharmaceuticals Ltd. Pharmaceutical composition of nintedanib esylate
WO2020068163A1 (fr) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5488880A (en) * 1977-10-06 1979-07-14 Eru Emu Asoshieito Yuugen Soft capsule
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5953410A (ja) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd 新型ソフトカプセル剤
JPS59157018A (ja) * 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS63238015A (ja) * 1987-03-24 1988-10-04 Morishita Jintan Kk 徐放性カプセル製剤
JPH01186815A (ja) * 1988-01-21 1989-07-26 Tokai Kapuseru Kk 軟カプセル剤およびその製造法
JPH01193216A (ja) * 1988-01-29 1989-08-03 Fuji Kapuseru Kk ソフトカプセル及び球状物
JPS6415A (en) * 1988-03-17 1989-01-05 Freunt Ind Co Ltd Absorption-improving drug preparation
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3159724B2 (ja) * 1991-04-19 2001-04-23 フロイント産業株式会社 シームレスカプセル製造方法および装置
JP3144865B2 (ja) * 1991-12-06 2001-03-12 エーザイ株式会社 軟カプセル剤
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
JPH0823912A (ja) * 1994-07-19 1996-01-30 Yoshinobu Umeda アシタバ入り食品
US5650232A (en) * 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
WO2003094897A1 (fr) * 2002-05-09 2003-11-20 Chugai Seiyaku Kabushiki Kaisha Capsule souple photostabilisee
KR100490279B1 (ko) * 2002-07-18 2005-05-17 주식회사 서흥캅셀 구취제거 및 구강 청량 효과를 지닌 젤라틴 연질캅셀제
US20070098787A1 (en) * 2003-06-20 2007-05-03 Mochida Pharmaceutical Co., Ltd. Composition for preventing and treating varicose veins of lower extremities
JP2005046054A (ja) * 2003-07-29 2005-02-24 Nippon Kayaku Co Ltd ダイエット食品及びダイエット用製剤
WO2005102291A1 (fr) * 2004-04-21 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. Capsule sans couture contenant un ingrédient actif soluble dans l'eau
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
WO2006073147A1 (fr) * 2005-01-04 2006-07-13 Mochida Pharmaceutical Co., Ltd. Agent thérapeutique contre la toxicité des graisses
EP1868567A4 (fr) * 2005-03-29 2010-09-29 Mcneil Ppc Inc Compositions contenant des medicaments hydrophiles dans un milieu hydrophobe
TW200714280A (en) * 2005-06-01 2007-04-16 Takeda Pharmaceuticals Co Novel method of treating hyperlipidemia
JP4327872B2 (ja) 2005-10-07 2009-09-09 トヨタ自動車株式会社 複数枚の回路基板を固定する固定部材とそれを利用したモジュール
CN101365438A (zh) * 2006-02-07 2009-02-11 持田制药株式会社 预防中风复发的组合物
JP4005104B2 (ja) * 2006-02-07 2007-11-07 持田製薬株式会社 脳卒中再発予防用組成物
WO2007103557A2 (fr) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2008000731A2 (fr) * 2006-06-26 2008-01-03 Valpharma S.A. Composition pharmaceutique destinée à l'administration par voie orale d'acides gras polyinsaturés oméga et d'au moins un principe actif incompatible avec eux, et procédé de préparation de celle-ci
WO2008088030A1 (fr) * 2007-01-17 2008-07-24 Mochida Pharmaceutical Co., Ltd. Composition destinée à la prévention ou au traitement d'une maladie associée à un thrombus ou à un embole
CN102552213A (zh) * 2007-06-29 2012-07-11 武田药品工业株式会社 无缝胶囊

Also Published As

Publication number Publication date
CO6290641A2 (es) 2011-06-20
BRPI0822019A2 (pt) 2015-07-21
AU2008345848A1 (en) 2009-07-16
MX2010007609A (es) 2010-08-04
CN103705487A (zh) 2014-04-09
NZ600720A (en) 2012-12-21
NZ587019A (en) 2012-07-27
CN103705486A (zh) 2014-04-09
UA100403C2 (en) 2012-12-25
DOP2013000085A (es) 2013-06-15
DOP2013000087A (es) 2014-01-31
US20100285121A1 (en) 2010-11-11
DOP2010000214A (es) 2010-07-31
EP2229939A4 (fr) 2011-04-27
AU2008345848B2 (en) 2014-05-15
EP2455070A1 (fr) 2012-05-23
MY157189A (en) 2016-05-13
CA2711814A1 (fr) 2009-07-16
IL206791A0 (en) 2010-12-30
UA102477C2 (en) 2013-07-10
UA102478C2 (en) 2013-07-10
EA201200829A1 (ru) 2012-11-30
ECSP10010395A (es) 2010-09-30
EP2455071A1 (fr) 2012-05-23
EA201070835A1 (ru) 2011-02-28
JP5421126B2 (ja) 2014-02-19
EP2229939A1 (fr) 2010-09-22
KR20100111292A (ko) 2010-10-14
EA201200830A1 (ru) 2012-11-30
WO2009087938A1 (fr) 2009-07-16
ZA201004793B (en) 2011-09-28
JPWO2009087938A1 (ja) 2011-05-26
CR11625A (es) 2010-09-29
CN101969932A (zh) 2011-02-09
NZ600721A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
MA32027B1 (fr) Preparation de capsules
MA38544A1 (fr) Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques
US9439878B2 (en) Use of lumefantrine and related compounds in the treatment of cancer
WO2007075475A3 (fr) Formes pharmaceutiques resistantes au reflux gastrique
CA2797558A1 (fr) Medicament pour traiter des affections hyperplasiques et inflammatoires chez l'humain a base de diindolylmethane
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MY160652A (en) Pharmaceutical composition for oral administration
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
MA33060B1 (fr) Formulations galéniques de composés organiques
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
EA202000165A1 (ru) ПРОТИВО-PHK ВИРУСНАЯ, В ТОМ ЧИСЛЕ ПРОТИВО-SARS-CoV-2 ВИРУСНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ АВИФАВИР
EA200800833A1 (ru) Фармацевтическая липидная композиция в виде частиц
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
FR2967576B1 (fr) Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament
ATE508737T1 (de) Clopidogrel-hydrogensulfat von polymorph 1 form enthaltende pharmazeutische zusammensetzung
MA38912A1 (fr) Formulations pharmaceutiques effervescentes pauvres en sodium
Kaya et al. Severe hyponatremia, epistaxis, and fluoxetine
MA30179B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique.
MA31744B1 (fr) Compositions pharmaceutiques lyophilisees
FR2920308B1 (fr) Forme pharmaceutique pour l'administration par voie orale de principes actifs.
Amponsahа Effect Of 30-Day Administration Of Cellgevityо Supplement On Selected Rat Liver Cytochrome P450 Enzyme Activity And Supplement Interaction With Carbamazepine
Amini et al. N-Acetylcysteine
TN2010000315A1 (en) Capsule formulation
EP4363398A1 (fr) Composés et procédés pour dégrader rcor1, lsd1, hdac1 et hdac2 en corest